Immune cells defective for Suv39h1

Patent metadata

Field	Value
Publication number	US-11285176-B2
Application number	US-202117507748-A
Country	US
Kind code	B2
Filing date	Oct 21, 2021
Priority date	Jun 20, 2017
Publication date	Mar 29, 2022
Grant date	Mar 29, 2022

Abstract

The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

First claim

The invention claimed is:

1. An engineered immune cell, wherein the immune cell is a T cell, NK cell, or progenitor thereof, comprising a genetically engineered antigen receptor and an inactivated or disrupted SUV39H1 gene, wherein inactivation or disruption of the SUV39H1 gene results in enhanced anti-cancer activity of said immune cell.

2. The immune cell of claim 1 , wherein the immune cell is a T cell or T cell progenitor.

3. The immune cell of claim 1 , wherein the immune cell is a CD4+ T cell, or a CD8+ T cell, or a CD4+ and CD8+ T cell.

4. The immune cell of claim 1 wherein the immune cell comprises a second genetically engineered antigen receptor that recognizes a different antigen.

5. The immune cell of claim 1 , wherein the genetically engineered antigen receptor is a T cell receptor (TCR).

6. The immune cell of claim 2 , wherein the genetically engineered antigen receptor is a T cell receptor (TCR).

7. The immune cell of claim 1 , wherein the genetically engineered antigen receptor is a chimeric antigen receptor (CAR).

8. The immune cell of claim 2 , wherein the genetically engineered antigen receptor is a CAR.

9. The immune cell of claim 1 , wherein the genetically engineered antigen receptor is a CAR comprising (a) an intracellular signaling domain from CD3 zeta chain and (b) one or more costimulatory domains of 4-1BB, CD28, ICOS, OX40 or DAP10.

10. The immune cell of claim 2 , wherein the genetically engineered antigen receptor is a CAR comprising (a) an intracellular signaling domain from CD3 zeta chain and (b) one or more costimulatory domains of 4-1BB, CD28, ICOS, OX40 or DAP10.

11. The immune cell of claim 1 , wherein the immune cell is autologous.

12. The immune cell of claim 1 , wherein the immune cell is allogeneic.

13. The immune cell of claim 1 , wherein the disrupted SUV39H1 gene comprises a deletion.

Assignees

• Inst Curie
• Inst Nat Sante Rech Med
• Centre Nat Rech Scient
• Centre National De La Rech Scientifique—Cnrs

Inventors

• Amigorena Sebastian
• Piaggio Eliane
• Goudot Christel
• Pace Luigia
• Almouzni Genevieve
• Niborski Leticia

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K40/15

  Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title